# Study of Surzebiclimab (BGB-A425) and Alcestobart (LBL-007) in Combination With Tislelizumab in Advanced Solid Tumors

> **NCT03744468** · PHASE1,PHASE2 · COMPLETED · sponsor: **BeiGene** · enrollment: 147 (actual)

## Conditions studied

- Locally Advanced or Metastatic Solid Tumors for Phase 1, Dose Escalation and Phase 2 Safety Lead-in
- HNSCC for Phase 2 Dose Expansion
- NSCLC for Phase 2 Dose Expansion

## Interventions

- **DRUG:** Surzebiclimab
- **DRUG:** Tislelizumab
- **DRUG:** Alcestobart

## Key facts

- **NCT ID:** NCT03744468
- **Lead sponsor:** BeiGene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-11-13
- **Primary completion:** 2025-02-06
- **Final completion:** 2025-02-06
- **Target enrollment:** 147 (ACTUAL)
- **Last updated:** 2026-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03744468

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03744468, "Study of Surzebiclimab (BGB-A425) and Alcestobart (LBL-007) in Combination With Tislelizumab in Advanced Solid Tumors". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT03744468. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*